Please provide your email address to receive an email when new articles are posted on . Adding itacitinib to standard prophylaxis may reduce GVHD incidence for patients who undergo haploidentical stem ...

Shi’s study, "Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling," was recently published in Nature Communications. “Concerted efforts ...

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and ...

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...

A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor (ICI)–induced type I ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.

Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and ...

DelveInsight’s, “Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline ...

In recent years, it’s been estimated that 10% to 28% of patients with myeloid disorders develop adult onset inflammatory and autoimmune disorders (IADs), complicating treatment. Treatment with Janus ...